Table 2 Summary of included studies employing short cognitive screening tools to assess cognitive impairment.

From: Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: a systematic review and meta-analysis

Study

Study design

Location

Endocrine therapy use

Sample size

Sample age (range, mean)

Assessment method

Methodological quality

Definition of cognitive decline

Time point(s)ǂ

Prevalence % (95% CIs where available)

Biglia 201249

Prospective Longitudinal

Italy

No

40

38–65, 51

MMSE

Moderate

Score under the mean

T2

31

Brezden 200025

Cohort

Canada

Yes

71 across two groups:

(1) Currently receiving chemotherapy, and (2) one year after cessation

34–70, 49

26–61, 46

HSCS

High

Classification as mild, moderate or severe according to pattern of scores as described by test authors

T1, T4

T1

Mild: 13

Moderate: 10

Severe:12/31 = 39

T4

Mild: 20

Moderate: 28

Severe:9/40 = 23

Fan 200526

Cohort

Canada

Yes

81

48 (median)

HSCS

High

Scores from each item on the test were subject to an algorithm which generated bands of impairment

T2,T4,T5

T2

Mild: 35

Mod-Severe: 16

T4

Mild: 30

Mod-severe: 4

T5:

Mild: 21

Mod-severe: 4

Fontes 201640

Prospective longitudinal

Portugal

Yes

475

54.7 (median)

MoCA

High

A MoCA score at least 2.0 standard deviations below age- and education-adjusted cut-offs

T3, T5

T3: 7

T5: 8

Ng 201852

Prospective Longitudinal

Singapore

Yes

166

50.7

Headminder computerized test

High

Reliable change index (RCI) score calculated to determine cognitive decline in each cognitive domain. A RCI score of lower than − 1.5 was used as criteria for decline

T1, T3

T1: 6.1–21.6

T3: 1.2–14.6

Pillai 201943

Prospective longitudinal

India

Yes

152

27–72, 47

MMSE

Low

MMSE score of ≤ 24 (out of 30)

T2,T3,T4,T5

T2: 0

T3: 0

T4: 0

T5: 0

Prokasheva 201161

Cohort

Israel

Yes

20

30–57, 49.3

Doors and people test

Moderate

Below 1SD as indicative of mild impairment and below 2SD for moderate impairment

T5

40

Ramalho 201762

Cohort

Portugal

Yes

418

27–87

MoCA

High

MoCA score values at least 1.5 standard deviations below age- and education-adjusted cut-offs

T3

8 (5.8, 11)

Tchen 200363

Cohort

Canada

No

110

27–60, 48

HSCS

High

Based on standard test criteria

T1

T1

Mild: 34

Moderate: 2

Severe: 14

  1. ǂT1 = During chemotherapy treatment, T2 = Just after cessation of treatment, T3 = 6 months after treatment cessation, T4 = 1 year after treatment cessation, T5 = 2–3 years after treatment cessation.